Cargando…

Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis

[Image: see text] Human IgG Fc glycosylation modulates immunological effector functions such as antibody-dependent cellular cytotoxicity and phagocytosis. Engineering of Fc glycans therefore enables fine-tuning of the therapeutic properties of monoclonal antibodies. The N-linked glycans of Fc are ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowden, Thomas A., Baruah, Kavitha, Coles, Charlotte H., Harvey, David J., Yu, Xiaojie, Song, Byeong-Doo, Stuart, David I., Aricescu, A. Radu, Scanlan, Christopher N., Jones, E. Yvonne, Crispin, Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2012
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593610/
https://www.ncbi.nlm.nih.gov/pubmed/23025485
http://dx.doi.org/10.1021/ja306068g
_version_ 1782262272594280448
author Bowden, Thomas A.
Baruah, Kavitha
Coles, Charlotte H.
Harvey, David J.
Yu, Xiaojie
Song, Byeong-Doo
Stuart, David I.
Aricescu, A. Radu
Scanlan, Christopher N.
Jones, E. Yvonne
Crispin, Max
author_facet Bowden, Thomas A.
Baruah, Kavitha
Coles, Charlotte H.
Harvey, David J.
Yu, Xiaojie
Song, Byeong-Doo
Stuart, David I.
Aricescu, A. Radu
Scanlan, Christopher N.
Jones, E. Yvonne
Crispin, Max
author_sort Bowden, Thomas A.
collection PubMed
description [Image: see text] Human IgG Fc glycosylation modulates immunological effector functions such as antibody-dependent cellular cytotoxicity and phagocytosis. Engineering of Fc glycans therefore enables fine-tuning of the therapeutic properties of monoclonal antibodies. The N-linked glycans of Fc are typically complex-type, forming a network of noncovalent interactions along the protein surface of the Cγ2 domain. Here, we manipulate the mammalian glycan-processing pathway to trap IgG1 Fc at sequential stages of maturation, from oligomannose- to hybrid- to complex-type glycans, and show that the Fc is structurally stabilized following the transition of glycans from their hybrid- to complex-type state. X-ray crystallographic analysis of this hybrid-type intermediate reveals that N-linked glycans undergo conformational changes upon maturation, including a flip within the trimannosyl core. Our crystal structure of this intermediate reveals a molecular basis for antibody biogenesis and provides a template for the structure-guided engineering of the protein–glycan interface of therapeutic antibodies.
format Online
Article
Text
id pubmed-3593610
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-35936102013-03-12 Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis Bowden, Thomas A. Baruah, Kavitha Coles, Charlotte H. Harvey, David J. Yu, Xiaojie Song, Byeong-Doo Stuart, David I. Aricescu, A. Radu Scanlan, Christopher N. Jones, E. Yvonne Crispin, Max J Am Chem Soc [Image: see text] Human IgG Fc glycosylation modulates immunological effector functions such as antibody-dependent cellular cytotoxicity and phagocytosis. Engineering of Fc glycans therefore enables fine-tuning of the therapeutic properties of monoclonal antibodies. The N-linked glycans of Fc are typically complex-type, forming a network of noncovalent interactions along the protein surface of the Cγ2 domain. Here, we manipulate the mammalian glycan-processing pathway to trap IgG1 Fc at sequential stages of maturation, from oligomannose- to hybrid- to complex-type glycans, and show that the Fc is structurally stabilized following the transition of glycans from their hybrid- to complex-type state. X-ray crystallographic analysis of this hybrid-type intermediate reveals that N-linked glycans undergo conformational changes upon maturation, including a flip within the trimannosyl core. Our crystal structure of this intermediate reveals a molecular basis for antibody biogenesis and provides a template for the structure-guided engineering of the protein–glycan interface of therapeutic antibodies. American Chemical Society 2012-10-01 2012-10-24 /pmc/articles/PMC3593610/ /pubmed/23025485 http://dx.doi.org/10.1021/ja306068g Text en Copyright © 2012 American Chemical Society
spellingShingle Bowden, Thomas A.
Baruah, Kavitha
Coles, Charlotte H.
Harvey, David J.
Yu, Xiaojie
Song, Byeong-Doo
Stuart, David I.
Aricescu, A. Radu
Scanlan, Christopher N.
Jones, E. Yvonne
Crispin, Max
Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis
title Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis
title_full Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis
title_fullStr Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis
title_full_unstemmed Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis
title_short Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis
title_sort chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593610/
https://www.ncbi.nlm.nih.gov/pubmed/23025485
http://dx.doi.org/10.1021/ja306068g
work_keys_str_mv AT bowdenthomasa chemicalandstructuralanalysisofanantibodyfoldingintermediatetrappedduringglycanbiosynthesis
AT baruahkavitha chemicalandstructuralanalysisofanantibodyfoldingintermediatetrappedduringglycanbiosynthesis
AT colescharlotteh chemicalandstructuralanalysisofanantibodyfoldingintermediatetrappedduringglycanbiosynthesis
AT harveydavidj chemicalandstructuralanalysisofanantibodyfoldingintermediatetrappedduringglycanbiosynthesis
AT yuxiaojie chemicalandstructuralanalysisofanantibodyfoldingintermediatetrappedduringglycanbiosynthesis
AT songbyeongdoo chemicalandstructuralanalysisofanantibodyfoldingintermediatetrappedduringglycanbiosynthesis
AT stuartdavidi chemicalandstructuralanalysisofanantibodyfoldingintermediatetrappedduringglycanbiosynthesis
AT aricescuaradu chemicalandstructuralanalysisofanantibodyfoldingintermediatetrappedduringglycanbiosynthesis
AT scanlanchristophern chemicalandstructuralanalysisofanantibodyfoldingintermediatetrappedduringglycanbiosynthesis
AT joneseyvonne chemicalandstructuralanalysisofanantibodyfoldingintermediatetrappedduringglycanbiosynthesis
AT crispinmax chemicalandstructuralanalysisofanantibodyfoldingintermediatetrappedduringglycanbiosynthesis